Introduction {#Sec1}
============

Radiotherapy (RT) has become an increasingly employed modality for treating hepatocellular carcinoma (HCC). However, few data are available on the tolerance of the liver to a second course of hepatic RT. The liver is susceptible to radiation damage; therefore, classic or nonclassic radiation-induced liver disease (RILD) has been reported within weeks or months after the administration of RT \[[@CR1]--[@CR3]\]. However, the guidelines for avoiding RILD apply only to patients planning to receive the first course of hepatic RT. Whether the same guidelines are applicable to previously treated patients is unclear. In particular, HCC is commonly accompanied by liver cirrhosis \[[@CR4]--[@CR6]\]. Therefore, investigating hepatic tolerance when a second course of RT is required is critical.

Studies examining clinical parameters for ensuring the safety of reirradiation for recurrent hepatoma are currently lacking. Hence, to optimize patient selection, we conducted this study to identify risk factors associated with hepatic toxicities and treatment outcomes after reirradiation. In this study, hepatic toxicities were classified according to all RILD and lethal RILD events. Our findings can provide information about the safety and selection criteria for patients with HCC requiring hepatic reirradiation.

Methods {#Sec2}
=======

Patient population {#Sec3}
------------------

In this study, we retrospectively analyzed the clinical data of patients who received 2 courses of RT to the liver between July 2004 and March 2014 at two hospitals. The inclusion criteria were the following: (1) a diagnosis of HCC based on tissue proof or the typical imaging appearance according to the criteria of the European Association for the Study of the Liver \[[@CR7]\]; (2) administration of prior RT for intrahepatic HCC; (3) residual or recurrent hepatic tumors either within or outside the previous irradiation field; (4) residual or recurrent tumors being unamenable to other treatments such as surgery, transarterial chemoembolization, and radiofrequency ablation; (5) an Eastern Cooperative Oncology Group performance score of 0--1; and (6) a Child-Pugh classification of A or B. The evaluation and treatment policies for the included patients were reviewed by a multidisciplinary team, and reirradiation was recommended.

Comprehensive clinical data of all patients were analyzed, including the age at reirradiation, the interval between the 2 courses of RT, liver function test (LFT) results, imaging study findings, and RT parameters before and after both courses of RT. The RT parameters comprised the clinical target volume (CTV), prescribed dose, normal liver reserve volume, and mean liver dose. The LFT results were the hepatitis B virus (HBV) or hepatitis C virus infection status; levels of serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), albumin, total bilirubin, and alkaline phosphatase; prothrombin time; and Child--Turcotte--Pugh (CTP) score. In total, 36 patients were included in this study; patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. The median age was 66 years, with a range of 32--80 years.Table 1Characteristics of all patientsPatients with RILDPatients without RILDVariables*N* = 13*N* = 23Gender Male1119 Female24Median age at reirradiation6471(range, 32 to 77)(range, 33 to 89)TNM stage (AJCC 7th edition) T1N0M024 T2N0M017 T3N0M059 T4N1M010 T3N0M143Previous local treatment Surgery12 TAE/TACE712 RFA/Cryo25Category of previous hepatitis Hepatitis B infection610 Hepatitis C infection26 non-HBV and non-HCV induced57 CTP scores before the 2nd RT6.3 ± 1.15.2 ± 0.5 Interval between 2 courses (months) abutting score for two PTV8.1 ± 8.112.6 ± 12.2 045 129 2791st RT parameters Mean prescribed dose (EQD~2~, Gy)49.5 ± 8.252.5 ± 5.7 Mean CTV (cm3)392.9 ± 407.0345.2 ± 565.0 Mean PTV (cm3)257.9 ± 207.8314.4 ± 480.7 Mean normal liver dose (EQD~2~, Gy)20.8 ± 11.320.1 ± 8.2 Mean normal liver volume (cm3)1255.5 ± 569.4926.5 ± 242.42nd RT parameters Mean prescribed dose (EQD~2~, Gy)32.9 ± 14.540.6 ± 12.8 Mean CTV (cm3)139.1 ± 150.2211.3 ± 343.1 Mean PTV (cm3)257.9 ± 207.8314.4 ± 480.7 Mean normal liver dose (EQD~2~, Gy)12.3 ± 6.610.2 ± 5.5 Mean normal liver volume (cm3)1173.4 ± 622.2992.5 ± 196.1 Mean cumulative prescribed dose (EQD~2~, Gy)80.9 ± 17.894.4 ± 13.9 Mean cumulative normal liver dose (EQD~2~, Gy)32.5 ± 15.130.5 ± 9.6*Abbreviation: RILD* radiation-induced liver disease, TNM stage was evaluated before reirradiation; *TAE* transarterial embolization, *TACE* transarterial chemo-embolization, *RFA* radiofrequency ablation, *Cryo* cryotherapy, *RT* radiotherapy, *CTV* clinical tumor volume, *PTV* planning target volume, *EQD2* biologically equivalent doses calculated in 2GyNote: abutting score: if reirradiation applied to a PTV separated from the previous PTV because the tumors were located at different segments, this situation was defined as out-field reirradiation (score = 0). For patients receiving reirradiation at the same or adjacent segment, the 2nd PTVs might be partially included in the previous PTV (score 1), or completely included (score 2)

Target delineation and RT planning {#Sec4}
----------------------------------

All patients underwent triphasic computed tomography (CT) or magnetic resonance imaging before treatment. The patients were immobilized using a vacuum bag with motion control using abdominal compression. CT simulation was performed using a 3-mm slice thickness with contrast enhancement; the simulation range included the entire liver, both lungs, and both kidneys. The gross tumor volume (GTV) was contoured as visible tumors on CT. The CTV was defined by leaving a 3--5-mm margin in three dimensions from the GTV or from the area adjacent to visible tumors where microscopic tumors were suspected. The planning target volume (PTV) was delineated as a 5-mm margin added to the CTV in three dimensions. The normal liver reserve was defined as the entire liver excluding all PTVs. According to recommended standards, the normal liver reserve was \>700 mL, and the mean dose was restricted to ≤23 Gy~2~ \[[@CR8], [@CR9]\]. In addition, the median dose to any kidney was less than 20 Gy~2~, the volume of the duodenum or stomach receiving more than 50 Gy~2~ was restricted to \<1 mL, the mean dose to the esophagus was less than 34Gy~2,~ and the cumulative doses to the spinal cord from two courses of RT was less than 60Gy~2~ \[[@CR10]\]. The same technique and similar constraints were used for both courses of RT.

All patients were treated using intensity-modulated RT (IMRT) with or without image guidance or image-guided tomotherapy. For patients treated with IMRT, static and coplanar procedures were used, whereas the X-ray energy depended on the tumor location. In case of image-guided IMRT, tumor location was verified with daily cone beam CT with or without the implantation of fiducial markers. A dose--volume histogram (DVH) was generated from a computerized planning system for rigorous evaluation. The prescribed doses for the 2 courses of RT in 36 patients were 30--60 Gy and 10--60 Gy with a fraction size of 1.8--3 Gy; 2 of the 36 patients received stereotactic body radiotherapy with a prescribed dose of 35 Gy in 5 fractions.

### Follow-up and toxicity definition {#Sec5}

A weekly clinical visit and routine LFT were rigorously conducted during and after the RT course. After the reirradiation course, these patients underwent scheduled LFTs and clinical assessment at least once in 2 weeks in the initial 3 months and monthly follow-up thereafter. For any patient developing ≥ grade 3 hepatic toxicities or rapid deterioration of liver function resulting in coagulopathy or encephalopathy, RT was discontinued immediately. When the LFT values deteriorated, the patients were admitted for daily evaluation and supportive care. All toxicities were classified according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4 \[[@CR11]\]. Classic RILD was defined as anicteric hepatomegaly and ascites with more than double the upper limit of the normal level of alkaline phosphate \[[@CR6]\]. Moreover, according to the CTCAE criteria, nonclassic RILD was defined as ≥ grade 3 hepatic toxicities, with more than 3 times the upper limit of the normal level of blood bilirubin or more than 5 times the upper limit of the normal levels of ALT or AST \[[@CR12]\]. Lethal RILD was defined as death directly caused by RT-related progressive hepatic failure before or without evidence of tumor progression.

In addition, we examined the impact of location of the two PTVs on the effect of RILD. Irradiation applied to recurrent tumors situated inside the previous PTV was defined as in-field reirradiation. Conversely, irradiation applied to a PTV separated from the previous PTV because the tumors were located at different segments was defined as out-field reirradiation (*N* = 9). For patients receiving reirradiation at the same or adjacent segment (*N* = 27), we proposed an abutting score for classify the location of two PTVs when assessing the impact of volume effect, as described in Table [1](#Tab1){ref-type="table"}.

Statistical analyses {#Sec6}
--------------------

The primary analysis was identifying the clinical parameters that could predict RILD and lethal RILD. The secondary analysis was identifying prognostic factors associated with survival after reirradiation. Logistic regression analysis was used to identify the predictors of RILD. Variables with a statistical significance in the univariate analysis were included in the multivariate analysis. Overall survival (OS) was defined as the time from the commencement of the second course of RT to the date of death from any cause or the final follow-up. Survival curves were calculated using the Kaplan--Meier method and log-rank test. Cox regression was performed to explore the prognostic factors for OS. The variables analyzed included age, the pretreatment LFT values (CTP score, albumin, total bilirubin, ascites), PTV, normal liver dose of the reirradiation, cumulative normal liver dose, duration, location of the two PTVs, and the presence of portal vein tumor thrombosis (PVTT). A 2-sided *p* value of \<0.01 was considered statistically significant. All statistical analyses were performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results {#Sec7}
=======

General outcomes {#Sec8}
----------------

The mean follow-up duration after reirradiation was 17 months (range, 3 to 74 months). Thirteen patients (36 %) developed RILD within 3 months after the initiation of reirradiation. All events were categorized as nonclassic RILD according to their clinical manifestation. Of the 13 patients, 2 could not complete the allocated RT regimen because of hepatic toxicities, and the prescribed doses were 20 Gy in 10 fractions and 21.6 Gy in 12 fractions. There was no evidence to show the continuous deterioration of liver function after the 1st course of RT. Although the previous RT might lead to a subclinical change of liver function, the RILD was mainly attributed to the consequence of reirradiation.

The details of both courses of RT are summarized in the [Appendix](#Sec17){ref-type="sec"}. We normalized the RT dose by using biologically equivalent doses calculated in 2 Gy as the α/β ratio of 15 for HCC \[[@CR13]\] and 8 for the adjacent hepatic tissues \[[@CR10]\]. In brief, the mean irradiation doses of the second course of RT for the hepatic tumor and normal liver tissue were 37.52 Gy~15~ (range, 10--58.68 Gy~15~) and 10.83 Gy~8~ (range, 2.5--23.97 Gy~8~), respectively. Moreover, the mean cumulative doses to the hepatic tumor and normal liver tissue were 87.70 Gy~15~ (range, 60.47--117.37 Gy~15~) and 31.11 Gy~8~ (range, 9.15--62.84 Gy~8~), respectively. The median interval between the 2 courses of RT was 11.0 months (range, 1--47 months).

Among the 13 patients with RILD, 4 had transient grade 3 hepatic toxicity, and the LFT values eventually returned to the normal range within 1 month after the completion of RT. Nine patients had lethal RILD without evidence of intrahepatic tumor progression; 8 patients died of fulminant hepatic failure within 3 months, and the remaining patient died of progressive liver failure 5 months after reirradiation. Furthermore, 2 patients did not complete the prescribed RT course because of a rapid deterioration of hepatic function during treatment, which LFT showed more than 5 times the upper limit of the normal levels of ALT or AST or more than 3 times the upper limit of the normal level of blood bilirubin. In addition to the 13 patients with RILD, 2 patients died of massive bleeding caused by esophageal and gastric varices within 6 months after reirradiation, which was a fatal complication of portal hypertension and classified as non-RILD related death. The other treatment-related adverse events such as RT-induced gastrointestinal bleeding, angiocholitis, and biliary stricture were not observed in this cohort.

Risk factors for RILD and lethal RILD {#Sec9}
-------------------------------------

To investigate the risk factors for RILD, clinical data, including the pretreatment LFT values, CTP score, and RT parameters before both courses of RT, were analyzed. As shown in Table [2](#Tab2){ref-type="table"}, several pretreatment LFT values and clinical parameters were associated with RILD in univariate analysis. Multivariate analysis revealed that a pretreatment CTP score ≥6 was a predictor of RILD \[odds ratio (OR): 15.83, 95 % confidence interval (CI): 2.95--85.08, *p* = 0.001\]. The results of univariate and multivariate analyses for lethal RILD are summarized in Table [3](#Tab3){ref-type="table"}. A preirradiation CTP score ≥6 was the only factor associated with lethal RILD \[OR: 72.56, 95 % CI: 3.650--1442.252, *p* = 0.005\]. No statistical differences were observed among all dosimetric parameters between patients with and those without RILD. In addition, the abutting score for the two PTVs and the treatment interval did not affect RILD. Furthermore, the pretreatment LFT before the 1st course of RT and normal liver dose or volume of the first RT course did not affect the occurrence of RILD after reirradiation ([Appendix](#Sec17){ref-type="sec"}).Table 2Risk factors associated with RILD after reirradiationVariablesRILD (+)RILD (−)UnivariateMultivariate*p* value*p* valueOR95 % CITotal number1323Liver function before 2nd RT Total bilirubin ≧2.0 mg/dL400.016 Albumin ≦3.5 g/dL840.007 Presence of ascites310.086 INR ≧1.7100 CTP score ≧6104\<0.00010.00115.8332.947 \~ 85.075 Presence of PVTT850.017 AST/ALT ≧3x of upper normal limit510.088Hepatitis Hepatitis B infection6100.877 Hepatitis C infection260.458RT parameters of 2nd RT Mean CTV (cm^3^)158.8 ± 157.9204.2 ± 348.70.740 Mean PTV (cm^3^)257.9 ± 207.8314.4 ± 480.70.260 Mean normal liver dose (EQD~2~, Gy~8~)12.0 ± 6.810.2 ± 4.80.726 Mean normal liver volume (cm^3^)1173.4 ± 622.2992.5 ± 196.10.332 Interval between 2 courses (month)8.1 ± 8.112.6 ± 12.30.247 Mean cumulative normal liver dose (EQD~2~, Gy~8~)32.0 ± 15.030.6 ± 9.70.233 Mean cumulative prescribed dose (EQD~2~, Gy~15~)82.8 ± 15.990.6 ± 15.40.065 Abutting score for two PTV1.3 ± 0.91.1 ± 0.70.548*Abbreviation: RILD* radiation-induced liver disease, *OR* odds ratio, *CI* confidence interval, *CTP* Child-Turcotte-Pugh, *PVTT* portal vein tumor thrombosis, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *CTV* clinical tumor volume, *NS* no significance, *EQD2* biologically equivalent doses calculated in 2GyTable 3Risk factors associated with lethal RILD after reirradiationVariablesLethal RILD (+)Lethal RILD (−)UnivariateMultivariate*p* value*p* valueOR95 % CITotal number927Liver function before 2nd RT Total bilirubin ≧2.0 mg/dL400.002 Albumin ≦3.5 g/dL660.001 Presence of ascites310.014 INR ≧1.7100 CTP score ≧686\<0.0010.00572.55543.650 \~ 1442.252 Presence of PVTT760.003 AST/ALT ≧3x of upper normal limit420.121Hepatitis Hepatitis B infection5110.439 Hepatitis C infection170.355RT parameters of 2nd RT Mean CTV (cm^3^)195.2 ± 166.9186.4 ± 331.70.806 Mean PTV (cm^3^)315.5 ± 224.5285.7 ± 447.70.890 Mean normal liver dose (EQD~2~, Gy~8~)9.7 ± 6.811.3 ± 5.20.019 Mean normal liver volume (cm^3^)1305.8 ± 687.6975.2 ± 210.50.078 Interval between 2 courses (month)6.0 ± 8.512.7 ± 11.40.119 Mean cumulative normal liver dose (EQD~2~, Gy~8~)27.9 ± 12.532.2 ± 11.50.221 Mean cumulative prescribed dose (EQD~2~, Gy~15~)75.0 ± 12.792.1 ± 14.70.005 Abutting score for two PTV1.4 ± 0.81.1 ± 0.80.824Abbreviation as Table [2](#Tab2){ref-type="table"}

Prognostic factors for OS {#Sec10}
-------------------------

At the time of this analysis, 32 patients died of disease progression with or without hepatic failure. Patients with RILD exhibited a shorter OS than did those without RILD, with the median survival being 5.7 and 29.0 months, respectively (*p* \< 0.001; Fig. [1](#Fig1){ref-type="fig"}). The median survival decreased to 3.8 months in patients with lethal RILD. In multivariate analysis, the presence of PVTT \[hazard ratio (HR): 12.41, 95 % CI: 2.05--12.41, *p* \< 0.001) and a CTP score ≥6 (HR: 8.79, 95 % CI: 1.48--6.74, *p* = 0.003) before reirradiation were prognostic factors. As depicted in Fig. [1](#Fig1){ref-type="fig"}, the median OS of patients with and without PVTT was 5 months and 22 months, respectively (*p* \< 0.001), whereas that of patients with CTP scores of ≥6 and 5 was 4 months and 18 months (*p* \< 0.001), respectively. No statistical difference was observed regarding OS for other clinical parameters, such as age, the irradiation interval, and the dosimetric parameters.Fig. 1Overall survival according to the occurrence of RILD, pre-reirradiation CTP score, and presence of PVTT. Abbreviation: RILD, radiation-induced liver disease; CTP, Child-Turcotte-Pugh; PVTT, portal vein tumor thrombosis

Discussion {#Sec11}
==========

In advanced HCC, RT is assumed to delay the time to tumor progression and resolves vascular damage caused by PVTT. However, the benefits are reduced by the increased risk of RT-related hepatic toxicities. Several studies have reported clinical parameters associated with RILD \[[@CR14]--[@CR18]\]; however, currently, no guidelines exist regarding hepatic tolerance or risk factors for RILD after reirradiation. This study is the first to reveal that a CTP score ≥6 is associated with an increased risk of RILD and predicts the occurrence of lethal RLID. In particular, the estimated OR was more than 10-fold higher than that of patients with a CTP score of 5. In addition, a high mortality rate can be anticipated in patients with a CTP score ≥6. In our study, patients with a pretreatment CTP score ≥6 had a median OS of less than 6 months; therefore, tailored selection is essential for patients requiring a second course of RT.

This study analyzed several pretreatment LFT parameters and concluded that the CTP score, which is widely used for the clinical assessment of liver cirrhosis, was a stronger predictor of hepatic toxicities than the other parameters. In addition, our study revealed that the duration between the 2 courses of RT and the dosimetric parameters did not affect the risk of hepatic toxicities, implying that residual liver function still plays a major role in determining the tolerance to reirradiation. This finding is consistent with the findings of several studies \[[@CR3], [@CR12], [@CR14]--[@CR17], [@CR19], [@CR20]\]. Yoon reported no correlation between RILD and DVH parameters, including the total liver volume, mean liver dose, V30, normal tissue complication probability (NTCP), and equivalent uniform dose \[[@CR15]\]. Cheng et al. proposed that patients with HCC having HBV infection and a Child--Pugh class of B have a high risk of RILD \[[@CR14]\]. Liang et al. suggested that the severity of hepatic cirrhosis is a major prognostic factor for RILD. In addition, some studies have suggested that the indocyanine green retention rate at 15 min (ICG-R15) is an accurate tool for predicting RILD \[[@CR15], [@CR16]\]. Lee et al. indicated that the CTP score is a more reliable predictor of RILD than is the ICG-R15 \[[@CR21]\]. By contrast, Pan et al. conducted quantitative analyses of normal tissue in a clinic and suggested applying stricter dose constraints to RT for HCC than for metastatic hepatic tumors, namely mean normal liver doses of less than 28 Gy for HCC and less than 32 Gy for liver metastases for therapeutic partial liver RT (in 2-Gy fractions) \[[@CR22]\]. To reach a widely accepted consensus, clinical trials analyzing comprehensive DVH data, clinical parameters, and the HBV titer should be conducted to determine patients with a high risk of RILD after reirradiation.

Although our study showed no impact of location of the two PTVs on RILD, the effect of the dose distribution pattern on outcomes requires further investigation. If recurrent tumors are situated inside the previous PTV, the surrounding hepatic tissues receive a summation of doses from both courses of RT. Dawson et al. proposed that a partial liver can tolerate more than 100 Gy if the volume is smaller than 25 % \[[@CR5]\]. By contrast, the cumulative low dose volume is larger when recurrent tumors are far from the previous PVTT. According to a similar NTCP model \[[@CR5]\], two-thirds of the total liver volume was assumed to tolerate doses of less than 48 Gy, whereas the total liver volume can tolerate doses of less than 32 Gy. In this study, we compared the cumulative dose to the normal liver rather than the detailed DVH profile because of the difficulty of summing DVHs from both courses of RT. Therefore, comprehensive DVH data should be retrieved for future analysis.

PVTT is an established prognostic factor for survival in patients with HCC receiving hepatic RT \[[@CR3]\]. Our study revealed that PVTT had a significant effect on OS after reirradiation. Therefore, in patients with PVTT, the risk of shortened survival should be considered before reirradiation. In a retrospective study of a cohort of 46 patients with HCC receiving RT \[[@CR3]\], Furuse et al. reported that PVTT exerted substantial effects on acute adverse hepatic toxicities, survival, and tumor response. They also confirmed that acute hepatic toxicities, including hyperbilirubinemia and hypoalbuminemia, were critical factors affecting survival. Therefore, in the future, we plan to clarify the association between the grade of the tumor thrombus and adverse hepatic events or treatment outcomes.

Our study results should be interpreted with caution. First, the results of this retrospective study with a limited sample size from 2 institutes should be prospectively validated using different irradiation schemes and patient populations. In addition, complete parameters of liver function such as gamma glutamyl transferase or virus titers were imperative to monitor the hepatic damage. Furthermore, the place of SBRT was still unclear in this study because of different biological dose effect compared to conventional radiotherapy. A prospective trial using SBRT for recurrent hepatic tumor is essential to maximize the therapeutic ratio. Finally, the conclusion can be strengthened by collecting and comparing more comprehensive DVH parameters. Thus, a modified NTCP model can be designed for obtaining an accurate score of the risk of RILD following reirradiation. Nonetheless, our study has implications for decision-making regarding initiating the second course of hepatic RT or stratifying patients in clinical trials. With more careful and thorough evaluation, this study can help radiation oncologists more meticulously re-treat patients with HCC, and survival benefits can be expected in patients who do not develop RILD. Early prediction of potential hepatic toxicities would enable administering individualized therapy to patients requiring a second course of hepatic RT.

Conclusion {#Sec12}
==========

Although this study included low number of patients into the analysis, a pretreatment CTP score ≥6 is associated with an increased risk of RILD and lethal RILD in patients requiring a second course of hepatic RT. Patients with RILD have a high mortality rate, implying that residual liver function plays a crucial role in determining the tolerance to reirradiation and survival after treatment. A multicenter prospective study is required to examine additional comprehensive risk factors for RILD.
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Abbreviation {#Sec16}
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ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; CTP, Child-Turcotte-Pugh; CTV, clinical target volume; DVH, dose--volume histogram; GTV, gross tumor volume; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ICG-R15, indocyanine green retention rate at 15 min; LFT, liver function test; NTCP, normal tissue complication probability; OS, overall survival; PTV, planning target volume; PVTT, portal vein tumor thrombosis; RILD, radiation-induced liver disease; RT, radiotherapy

Appendix {#Sec17}
========

Table 4Pretreatment liver function before the 1st course of RT and the association with RILD after reirradiationVariablesRILD (+)RILD (−)Univariate*p* valueTotal number1323Liver function before 1st RT Total bilirubin ≧2.0 mg/dL00 Albumin ≦3.5 g/dL530.54  [Ascites]{.ul}00 INR ≧1.7100 CTP score ≧6420.77 AST/ALT ≧3x of upper normal limit320.38Presence of PVTT530.75RT parameters Mean PTV of the 1st RT (cm^3^)605.7 ± 551.5410.6 ± 667.60.41 Mean normal liver dose of 1st RT (EQD~2~, Gy~8~)20.8 ± 12.021.3 ± 8.70.87 Mean normal liver volume of 1st RT (cm^3^)1255.5 ± 592.41055.3 ± 274.30.17*Abbreviation: RILD* radiation-induced liver disease, *OR* odds ratio, *CI* confidence interval, *CTP* Child-Turcotte-Pugh, *PVTT* portal vein tumor thrombosis, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *CTV* clinical tumor volume, *NS* no significance, *EQD2* biologically equivalent doses calculated in 2Gy
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